Viking Non Current Liabilities Total from 2010 to 2025
| VKTX Stock | USD 27.82 0.50 1.77% |
Non Current Liabilities Total | First Reported 2014-03-31 | Previous Quarter 766 K | Current Value 755 K | Quarterly Volatility 1.7 M |
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 319 K, Interest Expense of 75.2 K or Selling General Administrative of 51.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.23. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
Viking | Non Current Liabilities Total |
Latest Viking Therapeutics' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Viking Therapeutics over the last few years. It is Viking Therapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Viking Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 1,163,669 | |
| Geometric Mean | 306,497 | |
| Coefficient Of Variation | 138.64 | |
| Mean Deviation | 1,160,876 | |
| Median | 630,000 | |
| Standard Deviation | 1,613,304 | |
| Sample Variance | 2.6T | |
| Range | 5M | |
| R-Value | 0.02 | |
| Mean Square Error | 2.8T | |
| R-Squared | 0.0006 | |
| Significance | 0.93 | |
| Slope | 8,023 | |
| Total Sum of Squares | 39T |
Viking Non Current Liabilities Total History
About Viking Therapeutics Financial Statements
Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 630 K | 1.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.